Wharton’s jelly mesenchymal stem cells: Future regenerative medicine for clinical applications in mitigation of radiation injury

doi:10.4252/wjsc.v16.i7.742

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-6)

Tables (1-3)

Sum=4

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=2

Jul 26, 2024 (publication date) through Jul 25, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Stem Cells. Jul 26, 2024; 16(7): 742-759
Published online Jul 26, 2024. doi: 10.4252/wjsc.v16.i7.742

Wharton’s jelly mesenchymal stem cells: Future regenerative medicine for clinical applications in mitigation of radiation injury

Prashasti Sharma, Dharmendra Kumar Maurya

Prashasti Sharma, Dharmendra Kumar Maurya, Life Sciences, Homi Bhabha National Institute, Mumbai 400094, Maharashtra, India

Prashasti Sharma, Dharmendra Kumar Maurya, Radiation Biology & Health Sciences Division, Bhabha Atomic Research Centre, Mumbai 400085, Maharashtra, India

Author contributions: Sharma P collected the references, drew the figures, and drafted the manuscript; Maurya DK contributed to the conception, design, editing, and finalizing of the review; All authors read and approved the final manuscript.

Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Dharmendra Kumar Maurya, BSc, MSc, PhD, Radiation Biology & Health Sciences Division, Bhabha Atomic Research Centre, 3-82-S, A-block, Modular Laboratory, Mumbai 400085, Maharashtra, India. dkmaurya@barc.gov.in

Received: March 18, 2024
Revised: May 28, 2024
Accepted: June 24, 2024
Published online: July 26, 2024
Processing time: 128 Days and 22.3 Hours

Core Tip

Core Tip: Stem cells, particularly Wharton’s jelly mesenchymal stem cells (WJ-MSCs), are pivotal in cell-based therapy due to their robust tissue repair abilities. While radiotherapy is a common cancer treatment, it often causes collateral damage to healthy tissues, reducing its efficacy. WJ-MSCs, resembling embryonic stem cells, exhibit superior differentiation and safety, making them ideal for both autologous and allogeneic transplants. This review emphasizes WJ-MSCs’ regenerative potential and clinical utility in alleviating radiation-induced injuries resulting from radiotherapy across various cancer types.